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Abstract 
Purpose: To evaluate the immunogenicity and types of immune response of a quality-controlled 
modified recombinant hepatitis B surface antigen (HBsAg) plasmid encoding HBsAg in mice.  
Methods: The characterized plasmid DNA was used in the immunization of Balb/c mice. Three groups 
of mice were intramuscularly injected with three different concentrations (50, 25 and 10 μg/100 μL) of 
the modified plasmid. Humoral immune response was monitored by enzyme-linked immunosorbent 
assay (ELISA), while cellular immune response was investigated by analysis of spleen cytokine profile 
(TNFα, IFN γ and IL2) as well as CD69 expression level in CD4 and CD8 positive cells.  
Results: In general, the activated CD4 cells showing intracellular cytokines were higher than CD8 
positive population of cells (p < 0.05). These findings indicate that the vaccine induced both a humoral 
and cellular immunity. Cytokine profile also showed high levels of TNFα, IFN γ and IL2 and CD69 
expression in the group of animals immunized at a dose of 10 µg when compared to control group (p < 
0.05).  
Conclusion: A 10 µg dose intramuscular injection of the modified DNA-based vaccine encoding HBsAg 
in mice induces both high humoral and cellular immune responses.  
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Hepatitis B (HB) is a potentially life-threatening 
liver infection caused by Hepatitis B virus (HBV) 
[1]. It is an important worldwide health concern, 
more than 240 million are chronic carriers 
according to World Health Organization (WHO) 
[2]. DNA-based immunization is an efficient 
technique to induce humoral (antibody) and 
cellular (T cell) immune responses. 
 
The use of DNA-based vaccines has recently 
attracted much attention and shown promising 
outcomes by stimulating the immune system [3]. 
The protection against HBV infection depends on 
strong antibody response. Th1-type and cytotoxic 
T cells (CTL) responses to HBV and the 
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associated antiviral cytokines (TNF-α, IFN-α, and 
IL-2) might play a major role in virus resolution 
during natural infection.  
 
Antigen presentation includes primarily foreign 
protein degradation in the host cells through 
association of proteolytic fragments with two 
different types of major histocompatibility 
complex (MHC) proteins (class I and class II 
MHC) which present degraded protein fragments 
to T-cells. Thus, the ability of DNA vaccine to 
elicit both humoral and cell mediated immune 
responses is a great advantage of using DNA 
vaccine [4]. 
 
The purpose of the present investigation was to 
assess the immunogenicity of previously 
reported DNA-HBsAg - based vaccine 
comprising modified gWiz-HBsAg plasmid, 
characterized and quality-controlled by Salem-
Bekhit et al [5], and type of immune responses 




Vector and expression plasmids  
 
The gWiz™ expression vector, used as control in 
the quality control experiments, and the hepatitis 
B DNA vaccine recombinant plasmid 
gWiz™HBsAg (gWiz™ plasmid harbours HBsAg 
encoding nucleotide sequence) were purchased 
from Aldevron, USA. The full integrity and quality 
of the nucleotide sequence of gWizHBsAg 
plasmid was characterized and previously 
controlled previously [5]. The quality controlled 
recombinant plasmid gWizHBsAg was used in 
mice immunization experiments performed in this 
study. 
 
Modified gWiz™HBsAg plasmid mice 
immunization 
 
The recombinant modified gWizHBsAg plasmid 
(6.435 kbp long and had a pUC origin of 
replication. Aldevron, USA). previously reported 
by Salem-Bekhit et al [5]. Briefly, The gWi zHBs 
have sequentially propagated in Escherichia coli 
DH5α strain, Genotype: F- endA1 glnV44 thi-1 
recA1 relA1 gyrA96 deoR nupG Φ80dlacZΔM15 
Δ(lacZYA-argF)U169, hsdR17(rK- mK+), λ. The 
gWiz high-Expression HBsAg plasmid 
(gWizHBsAg) 5 mg. The prepared plasmid was 
analyzed, using agarose gel electrophoresis, 
DNA restriction profiling and DNA sequencing. 
The gWizHBsAg plasmid was used for 
immunization of 21 female Balb/c mice aged 6–8 
weeks bred in King Saud University (KSU) 
animal house and kept under specific pathogen 
free conditions. These mice were divided into 
three groups (A, B and C), each group comprised 
seven mice. Mice received intramuscular (IM) 
injections by insulin syringe (Becton-Dickinson, 
Franklin Lakes, NJ, USA) in the quadriceps 
muscles of the hind limbs. The three groups A, B 
and C received different doses of gWizHBsAg 
plasmid DNA dissolved in 100 μL of normal 
saline 50 μg/100 μL, 25 μg/100 μL and 10 
μg/100 μL, respectively. Mice were boosted with 
a dose of 4 μg after 2 weeks from the initial 
immunization. Ethical approval for the animal 
study was obtained from the Ethics Committee of 
the College of Pharmacy, KSU, Riyadh, Saudi 
Arabia. 
 
Mice bleeding and detection of specific 
antibodies against HBsAg  
 
Serial bleedings were performed at different time 
points starting with pre-immunization bleeding at 
the beginning and then at weekly interval up to 6 
weeks after the first immunization. The blood 
samples were analyzed for the presence of 
HBsAg-specific IgM antibodies from week 0, 1, 2, 
3 and 4 and starting from weeks 3, 4, 5 and 6 for 
the detection of HBsAg-specific IgG antibodies. 
Microtitre plates of ELISA kits (Alpha Diagnostic 
International, U.S.A) coated with HBsAg protein 
were used for the detection anti-HBsAg 
antibodies. In brief, 100 μL of serum diluted in 
1:200 was added to each well then incubated for 
one hour at 25 oC. After the samples were 
washed with PBS, bound proteins were detected 
with HRP-conjugated goat anti-mouse IgM or 
anti-mouse IgG. Color was generated by adding 
reaction stop solution and the absorbance was 
measured at 450 nm by ELISA reader. ELISAs 
were performed and HBsAg specific IgM and IgG 
antibodies were calculated according to the 
manufacturer’s instructions. 
 
Isolation and culturing of splenocytes 
isolated from immunized mice  
 
To determine the cellular reaction of the modified 
gWizHBsAg plasmid immunization, the spleen, 
following six-week immunization course, were 
isolated from the three groups of mice, A, B, and 
C, and splenocytes were cultured as follows. 
Briefly, immediately after mouse sacrifice, spleen 
was put in a clean Petri-dish with a suitable 
tissue culture medium, disrupted mechanically 
using a 5 ml syringe head after cutting into small 
pieces and passed through a nylon cell strainer 
(Becton Dickinson, New Jersey, USA). 
Contaminating red blood cells were lysed using 
0.83 % ammonium chloride and incubated at 37 
oC for 5 min. In ice-cold RPMI 1640 tissue culture 
medium supplemented with 10 mM fetal bovine 
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serum, 10 mM HEPES, 2 mM glutamine, 100 
U/mL streptomycin and 100 U/mL penicillin the 
cells were suspended. 
 
Finding of splenocytes surface markers and 
intracellular cytokines  
 
HBsAg-specific CTL assay was performed using 
panels of monoclonal antibodies used for the 
detection of surface markers and intracellular 
cytokines of immunized splenocytes. Splenocyte 
concentration of 2 x 106 /mL was stained in 4 test 
tubes:- 1- CD4 FITC, CD69 PE and Tumor 
Necrosis Factor (TNF) precp, 2- CD4 FITC, IL2 
PE and INF-γ precp., 3- CD8 FITC, CD69 PE 
and TNF precp., 4- CD8 FITC, Interleukin-2 (IL2) 
PE and INF-γ precp. Surface marker monoclonal 
antibodies were added first to stain the cells for 
20 min in the dark, cells were then washed with 
cold 5 % BSA/PBS and the pellet was re-
suspended in complete RPMI. The cells were 
fixed and permeablized with 100 μL of BD 
Cytofix/Cytoperm buffer and incubated for 20 min 
at room temperature. Thereafter, 20 μL of 
cytokine monoclonal antibodies were added, 
incubated for 15 min, washed 3 times and 
suspended in BD Pharmingen stain buffer. Data 





The data were processed by SPSS 11.5 
software. For each set of data, mean and 
standard deviation (SD) were calculated. IgM 
and IgG values were plotted against time and 
histograms were built to compare the values 
obtained for cytokines. Statistical significance of 




DNA plasmid encoding HBsAg induces 
humoral immune response in BALB/c mice 
 
The humoral immunity was evaluated by 
detecting specific HBsAg IgG and IgM induced 
by modified DNA HBsAg plasmids in BALB/c 
immunized mice. ELISAs results showed that 
HBsAg specific IgG and IgM antibodies were 
detectable in the sera of the immunized mice 
groups A, B and C. The baseline reading of the 
pr-immunization bleed sera showed an OD450nm 
of 0.15. The group A mice, which received a total 
of 20 mg of modified plasmid DNA-HBsAg over 
the six-week immunization course, demonstrated 
IgM antibodies as early as one week after the 
first immunization showing a detectable signal at 
an OD450nm of 2.8. However, in the following 2nd 
and 3rd weeks showed a gradual drop to an 
OD450nm of 1.5. However, at the 4th week, the 
IgM level showed a rise up to OD450nm of 2.0. IgG 
antibodies were detectable starting from the 3rd 
week after the first immunization giving an 
OD450nm of 0.18. Thereafter, IgG level started to 
decrease gradually in the 5th and 6th weeks to 
0.1 OD450nm. The collective results for IgM and 
IgG levels for group A mice are shown in Figure 
1A. 
 
In immunized mice group B, which received a 
total of 10 mg of modified DNA-HBsAg plasmid 
by the I.M. route, IgM antibodies were detectable 
at a level of 0.35 OD450nm in the sera of the first 
bleed sample after one week of immunization. In 
the following bleedings at the 2nd, 3rd and 4th 
week, the IgM antibodies levels were almost 
maintained. On the other hand, IgG antibodies 
were detectable at a level of 1.0 OD450nm in the 
3rd week. The level of IgG antibodies was then 
increased to 0.15 OD450nm in the 4th week and to 
2.5 OD450nm in the 5th week. Afterwards, the level 
of IgG antibodies started to decrease gradually to 
a level of 0.1 OD450nm at the 6th week. The 
collective results for IgM and IgG levels for this 
group are shown in Figure 1B. 
 
In group C mice which received a total of 4 mg of 
modified plasmid DNA-HBsAg over the 
immunization course, IgM antibodies level were 
detectable after one week from the first 
immunization of 0.35 OD450nm. The level dropped 
gradually to 0.3 and 0.29 OD450nm in the 2nd and 
3rd week bleeds, respectively, and then 
increased to 0.3 OD450nm at the 4th week. The 
IgG antibodies level were detectable in a level of 
0.15 OD450nm at the 3rd week, then the level 
increased to 0.22 OD450nm in the 4th week and 
dropped to 0.15 OD450nm at 5th week. At the 6th, 
week the IgG antibodies level again increased to 
0.2 OD450nm. The collective IgM and IgG 
antibodies levels for this group are shown in 
Figure 1C. 
 
Activation of cellular immunity in BALB/c 
mice  
 
The cellular immunity in DNA-HBsAg plasmid 
immunized BALB/c mice was assessed by 
detecting the CD4+ and CD8+ cells. Activation of 
CD4+ and CD8+ cells was examined in the three 
groups of immunized mice by measuring the 
number of cells showing intracellular cytokine 
release, TNF, INF-γ and IL-2. The activation 
marker CD69 was also measured.  
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Figure 1: HBsAg-specific IgM and IgG levels in modified plasmid DNA-HBsAg immunized mice groups following 
I.M injection over the six-week immunization course: A, group A which treated with 40 mg of modified plasmid; B, 
group B which treated with 20 mg of modified plasmid; C, group C which treated with 4 mg of modified plasmid 
 
Activation of CD4+ cells for the three groups of 
immunized mice is shown in Figure 2A. It was 
found that 30 % of CD4+ cells in group C mice 
were actually producing TNF as compared to 21 
and 5 % in groups A and B, respectively. For 
INF-γ as shown in Figure 2A, 28 % of CD4+ cells 
from mice group C showed detectable 
intracellular INF-γ. While, in groups B and A, 
mice 20 and 8 % of the CD4+ cells were actively 
producing INF-γ, respectively. CD4+ cells from 
group B mice showed 18 % of activated cells 
secreting IL-2, while, it is 10 % in group C and 
only 2 % in group A. The activation marker, 
CD69, was detected in equal number in both 
group B and group C where 14 % of the CD4+ 
cells were positive, however, in group A, only 4 
% of the CD4+ cells were positive for the marker. 
 
In the case of CD8+ cells (Figure 2B), 
intracellular TNF was detected in 23 % of cells in 
group C, mice while 18 % in group B and 2.5 % 
in group A were secreting TNF. For INF-γ, CD8+ 
cells from group C mice showed also the highest 
number of activated cells secreting INF-γ (24 %). 
In group B, mice 18 % of cells were active and in 
group A only 4 % of cells showed INF-γ. IL-2 was 
detected in 5 % of the cells from mice group C; 
mice while in groups A and B, only 2 % were 
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positive for IL-2. CD8+ cells from group C mice 
showed 15 % of cells expressing CD69, while the 
marker was only detected in 2 and 5 % of CD8+ 




The best way to prevent hepatitis B is by 
receiving hepatitis B vaccine. It is important to 
accelerate the vaccination schedule against 
hepatitis B because it might increase patient 
compliance in addition to offering earlier 
protection for the high-risk group or environment. 
HBV infection is considered to be one of the 
dominant problem in most countries worldwide, 
specifically those in the Middle East, Asia, and 
Africa [6-8]. Hepatitis B infection is the major 
cause of diseases of liver such as cirrhosis and 
hepatic carcinoma. Despite the occurrence of 
HBV infection that has declined fallowing mass 
HB vaccination programs, the average incidence 
of chronic HBV infection internationally is 
estimated at 6.6 % [7]. The rate of HbsAg 
positivity among the vaccinated group was 0.8 % 
in comparison with 2.2 % among the non-
vaccinated group. The study concluded that the 
efficacy of HB vaccine in inhibiting the carriage of 
HbsAg, 5 years after full course vaccination, was 
assessed to be around 67 % in Egypt [9]. 
 
One month [10] after the third dose, the 
seroprotection was (96.5 %) with mean 
geometric anti-HBs titers of 2 560.0 mIU/mL was 
indicated through the experimental data that 
were obtained during the trial course. In addition, 
twenty subjects as a whole in the age group of 
40-49 years (11/307; 3.5 %) had resulted an 
antibody titer of 8.60 mIU/mL and presented a 
low response to the vaccine. While all tested 
subjects attained 100 % seroconversion [11], risk 
factors associated with non-response to hepatitis 
B vaccine included age, gender, history of 
smoking and route of administration of vaccine 
[12]. 
 
Viral vectors and recombinant DNA have been 
used for years in human clinical trials and in 
laboratory animals as vectors for Ag(s) of interest 
to make strong effector and memory CD4_ and 
CD8_ T cell responses in both the treatment and 
inhibition of diseases [13-15].  
 
Results from this study show that both humoral 
and cellular immune responses were induced in 
mice by the intramuscular injection of a modified 
plasmid DNA-HBs Antigen. In all three groups of 
mice, A, B and C which received 20, 10 and 4 µg 
of vaccine, respectively, the antibodies of IgM 
class were detectable at a comparatively high 




Figure 2: Assessment of cellular activation in modified plasmid DNA-HBsAg immunized mice groups following 
I.M injection: A, data for CD4+ cells; B, data for CD8+ positive cells, data for four the three immunized groups A, 
B, C and fourth negative control group D 
 
Salem-Bekhit et al 
Trop J Pharm Res, April 2016; 15(4): 692  
 
This finding confirms the induction of a primary 
response to the injected vaccine (16). It has been 
documented that specific cellular immunity 
against HBV is a key factor in the control of HBV 
infection [17,18]. IgM level decreased gradually 
in all three groups over the following two weeks 
and then showed a rise at the 4th week. As a 
consequence of the booster doses given to the 
animals, IgG type of antibodies appeared the 3rd 
week in all the groups. This indicates a normal 
secondary response to the injected vaccine. The 
IgG level started to decrease gradually 
thereafter. It is also noted that IgM showed 
higher levels as compared to IgG. This could be 
due to the concentration of the booster doses 
administered.  
 
Compared to groups A and B, group C showed 
the best results. This may be taken to indicate 
that the best immunizing dose in this experiment 
lies in the range of 4 µg. In this group, higher 
levels of IgM were detected and showed a 
sustained level up to the 4th week. IgG 
antibodies became detectable at the 3rd week 
and also maintained an almost constant level up 
to the 6th week. Cellular responses to the 
modified DNA-HBs antigen vaccine were 
assessed in splenocytes isolated from the 
immunized mice by measuring intracellular 
cytokines (IFN-γ, TNF, IL-2 and the activation 
marker CD69) in CD4+ and CD8+ cells. In 
general, the percent of activated CD4+ cells 
showing intracellular cytokines was higher than 
the CD8+ population of cells. This is expected 
since CD4+ helper cells are usually higher than 
CD8+ cytotoxic cells.  
 
Another observation worthy of note, the 
cytokines detected IFN-γ and TNF indicates a 
Th2 type of response. Viral antigens are known 
to drive T-helper cells into the Th2 type. It is also 
interesting to note that group C mice again 
showed the best cellular response. As appeared 
in the results, IL-2 was the least cytokine 
detected and the number of CD8+ cells secreting 
this cytokine was very low. In summary, results 
from this experimental study in BALB/c mice 
demonstrated that I.M. injection of a DNA-HBs 
antigen in a dose of 10 µg induced both humoral 
and cellular immune responses. Further studies 
may be needed to adjust the dose and timing of 
the booster doses to give a sustained immune 
response. Engaging therapeutic hepatitis B 
vaccines is a new approach against hepatitis B 
infection [19,20]. The cytokines (IFN-γ, TNFα, IL-
2 and CD69) in CD4+ and CD8+ cells perform a 
vital role in various stages of viral infection [21-
24]. However, experiments which are carried out 
in vivo and in vitro showed that secretion of Th1 
cytokines (IFN-γ and TNF-α) play an important 
part in HBV elimination from hepatocytes [25,26]. 
Hepatitis B vaccine administered through gene 
therapy showed enhanced cytokines level in 
patients with Hepatitis B. The direct 
administration of cytokines seems to be a more 




The findings of this study demonstrate that I.M. 
injection of a DNA-HBs antigen at a dose of 10 
µg induces both humoral and cellular immune 
responses in BALB/c mice. Further studies are 
required to adjust the dose and timing of the 
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